252944-01-7

Basic information

• Product Name: N6-(2-Aminoethyl)-3-nitro-2,6-pyridinediamine
• Synonyms: N6-(2-Aminoethyl)-3-nitro-2,6-pyridinediamine;(2-AMinoethyl)(6-aMino-5-nitro-2-pyridyl)aMine;2,6-Diamino-N2-(2-aminoethyl)-5-nitropyridine
• CAS NO: 252944-01-7
• Molecular Formula: C₇H₁₁N₅O₂
• Molecular Weight: 197.19454
• Product Categories: Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Amines, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 252944-01-7.mol

Chemical Properties

• Boiling Point: 455.398 °C at 760 mmHg
• Flash Point: 229.217 °C
• Appearance: /
• Density: 1.445 g/cm³
• Solubility: DMSO
• PKA: 8.98±0.10(Predicted)
• CAS DataBase Reference: N6-(2-Aminoethyl)-3-nitro-2,6-pyridinediamine(CAS DataBase Reference)
• NIST Chemistry Reference: N6-(2-Aminoethyl)-3-nitro-2,6-pyridinediamine(252944-01-7)
• EPA Substance Registry System: N6-(2-Aminoethyl)-3-nitro-2,6-pyridinediamine(252944-01-7)

Safety Data

• Hazardous Substances Data: 252944-01-7(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Upstream product

• 27048-04-0 2-amino-6-chloro-3-nitropyridine 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 107-15-3 ethylenediamine 

Downstream Products

• 252950-26-8 2-{N-[2-({2-[(6-amino-5-nitro(pyridin-2-yl))amino]ethyl}amino)-4-(2,4-dichlorophenyl)pyrimidin-5-yl]carbamoyl}benzoic acid 
• 252950-32-6 tert-butyl 4-[2-({2-[(6-amino-5-nitro(2-pyridyl))amino]ethyl}amino)-4-(2,4-dichlorophenyl)pyrimidin-5-yl]piperazinecarboxylate 
• 252936-31-5 N-[2-({2-[(6-amino-5-nitro(2-pyridyl))amino]ethyl}amino)-4-(2,4-dichlorophenyl)pyrimidin-5-yl]-2-(dimethylamino)acetamide 
• 252936-34-8 N-[2-({2-[(6-amino-5-nitro(2-pyridyl))amino]ethyl}amino)-4-(2,4-dichlorophenyl)pyrimidin-5-yl]-4-morpholin-4-ylbutanamide 
• 252942-07-7 {2-[(6-amino-5-nitro(2-pyridyl))amino]ethyl}{5-imidazol-2-yl-4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl}amine 
• 252942-06-6 4-[2-({2-[(6-amino-5-nitro(2-pyridyl))amino]ethyl}amino)-5-imidazol-2-ylpyrimidin-4-yl]benzenecarbonitrile 
• 252942-09-9 {2-[(6-amino-5-nitro(2-pyridyl))amino]ethyl}[4-(2-chlorophenyl)-5-imidazol-2-ylpyrimidin-2-yl]amine 
• 252942-11-3 {2-[(6-amino-5-nitro(2-pyridyl))amino]ethyl}{4-[4-fluoro-2-(trifluoromethyl)phenyl]-5-imidazol-2-ylpyrimidin-2-yl}amine 
• 252942-15-7 {2-[(6-amino-5-nitro(2-pyridyl))amino]ethyl}[4-(4-bromo-2-chlorophenyl)-5-imidazol-2-ylpyrimidin-2-yl]amine 

Relevant articles and documents

Inhibitors of glycogen synthase kinase 3

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Inhibitors of glycogen synthase kinase 3

Novel pyridine and pyrimidine derivatives which selectively inhibit glycogen synthase kinase 3 are provided and methods of preparing these compounds are provided. These compounds are useful in treating certain conditions which may be mediated by glycogen synthase kinase 3.